A single-center experience with magnetically levitated left ventricular assist device for treatment of end-stage heart failure

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F20%3A00080688" target="_blank" >RIV/00023001:_____/20:00080688 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.cesurg.ru/en/jarticles_cesurg/426.html?SSr=190134622813ffffffff27c__07e502100d1311-72ec" target="_blank" >https://www.cesurg.ru/en/jarticles_cesurg/426.html?SSr=190134622813ffffffff27c__07e502100d1311-72ec</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.33029/2308-1198-2020-8-3-7-16" target="_blank" >10.33029/2308-1198-2020-8-3-7-16</a>

Jazyk výsledku

angličtina

Název v původním jazyce

A single-center experience with magnetically levitated left ventricular assist device for treatment of end-stage heart failure

Popis výsledku v původním jazyce

Background. The HeartMate 3 Left Ventricular Assist System is a recent compact fully magnetically levitated centrifugal-flow continuous ventricular assist device engineered to enhance hemocompatibility. The aim of this study was to evaluate clinical characteristics, adverse event rates, survival and outcomes of patients supported with HeartMate 3 LVAS. Material and methods. We retrospectively reviewed a cohort of consecutive 150 patients implanted with HeartMate 3 LVAS at a single institution between April 2016 and June 2020. Results. The study comprised of 150 patients (125 male; 83%) aged 57.2±11.9 years, with majority in INTERMACS profile 3 (n=65; 43.3%). During 4-year follow-up 32 patients were transplanted, 37 had died, 78 are ongoing and in 3 (2%) patients had a myocardial recovery. The actuarial survival after device implantation was 77.6, 74.6, 74.6 and 69.9% at 12, 24, 36 and 48 months respectively. 46 (31%) patients were implanted temporary RVAD. Other most frequent adverse events included infections (74 patients; 49.3%), major bleeding (38; 25.3%) or neurological dysfunction (16; 10.6%). Conclusion. We have observed survival rates comparable with international registries using the HeartMate 3 LVAS for long-term circulatory support. The results of the study confirm high reliability of the system, enhanced hemocompatibility and improved adverse event rates, nevertheless, some complications remain a concern. © 2020 GEOTAR Media. All rights reserved.

Název v anglickém jazyce

A single-center experience with magnetically levitated left ventricular assist device for treatment of end-stage heart failure

Popis výsledku anglicky

Background. The HeartMate 3 Left Ventricular Assist System is a recent compact fully magnetically levitated centrifugal-flow continuous ventricular assist device engineered to enhance hemocompatibility. The aim of this study was to evaluate clinical characteristics, adverse event rates, survival and outcomes of patients supported with HeartMate 3 LVAS. Material and methods. We retrospectively reviewed a cohort of consecutive 150 patients implanted with HeartMate 3 LVAS at a single institution between April 2016 and June 2020. Results. The study comprised of 150 patients (125 male; 83%) aged 57.2±11.9 years, with majority in INTERMACS profile 3 (n=65; 43.3%). During 4-year follow-up 32 patients were transplanted, 37 had died, 78 are ongoing and in 3 (2%) patients had a myocardial recovery. The actuarial survival after device implantation was 77.6, 74.6, 74.6 and 69.9% at 12, 24, 36 and 48 months respectively. 46 (31%) patients were implanted temporary RVAD. Other most frequent adverse events included infections (74 patients; 49.3%), major bleeding (38; 25.3%) or neurological dysfunction (16; 10.6%). Conclusion. We have observed survival rates comparable with international registries using the HeartMate 3 LVAS for long-term circulatory support. The results of the study confirm high reliability of the system, enhanced hemocompatibility and improved adverse event rates, nevertheless, some complications remain a concern. © 2020 GEOTAR Media. All rights reserved.

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

30212 - Surgery

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical and experimental surgery

ISSN

2308-1198

e-ISSN

—

Svazek periodika

8

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

RU - Ruská federace

Počet stran výsledku

10

Strana od-do

7-16

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-85098684874